 SAN DIEGO, Feb. 18, 2021 GLOBE NEWSWIRE -- Travere Therapeutics, Inc. NASDAQ: TVTX today announced the European Commission EC has granted orphan designation to sparsentan for the treatment of IgA nephropathy IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease ESKD. Sparsentan is an investigational product candidate currently being evaluated in a pivotal Phase 3 clinical study for the treatment of IgAN, as well as a pivotal Phase 3 clinical study for the treatment of focal segmental glomerulosclerosis FSGS. The Company recently reported that the ongoing DUPLEX Study of sparsentan in FSGS achieved its pre-specified interim proteinuria endpoint and that preliminary results from the interim analysis suggest that to date in the study, sparsentan has been generally well-tolerated and has shown a comparable safety profile to irbesartan. Topline data from the interim proteinuria assessment in the ongoing PROTECT Study of sparsentan in IgAN remain on track to be reported in the third quarter of 2021. 